Jill Wechsler

Jill Wechsler is BioPharm International's Washington Editor, jillwechsler7@gmail.com.


Trump’s Revenge on Pharma

The Trump administration unveiled a new drug price control policy, drawing opposition from pharma manufacturers and pharmacy benefit managers.

FDA May Delay Approval of Drugs Where Necessary Inspection Is Not Feasible

A new FDA guidance provides answers to such questions about when the agency will seek to visit a site during the COVID-19 pandemic and how it will respond when a needed inspection cannot be conducted safely.

Global Regulatory Collaborations Aim to Speed Access to New Vaccines and Drugs

Efforts by regulators seek common approaches to clinical research and biopharmaceutical production needed to wipe out the coronavirus pandemic globally.

Stakeholders Seek Increased User Fee Support for Biologics

Patient advocates, research experts, and industry are calling for more user fee revenues to support CBER programs to advance innovative therapies.